Assessing outcomes in patients with advanced solid tumors receiving non-standard therapies
Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)
This study is testing how well non-standard treatments work for patients with advanced solid tumors by using personalized treatment plans based on their unique genetic profiles.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 21 Years to 99 Years |
| Sex | All |
| Sponsor | National Cancer Centre, Singapore Academic / other |
| Locations | 1 site (Singapore) |
| Trial ID | NCT06956248 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of off-label or non-standard therapies for patients with advanced treatment refractory solid tumors, guided by molecular profiling results discussed at a molecular tumor board. The study aims to standardize response assessments and data collection for these patients, tracking their treatment responses over time. Participants will undergo comprehensive molecular profiling, and their treatment decisions will be based on recommendations from the tumor board. The study will also collect translational tissue and plasma samples for further research.
Who should consider this trial
Good fit: Ideal candidates are adults aged 21 and older with advanced solid tumors who have failed all standard treatments or are unsuitable for further standard therapies.
Not a fit: Patients with specific contraindications to the off-label therapies or significant comorbid conditions that may hinder outcome assessments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment outcomes for patients with advanced cancers by providing tailored therapies based on molecular profiling.
How similar studies have performed: Other studies have shown promise in using molecular profiling to guide treatment decisions, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Is equal to or greater than 21 years of age; 2. Histologic or cytologic confirmed advanced solid tumours; 3. Patients who have received and failed all standard anticancer therapy (if available) or are unsuitable for further standard anticancer therapy. Cancers with a poor prognosis or low expected response rate to standard treatment (as judged by the investigator on the basis of available evidence) may be screened with respect to an earlier line of treatment; 4. Ability to understand and the willingness to provide written informed consent. Exclusion Criteria: 1. Specific contraindications to exposure to the off-label or non-standard therapy (as defined by the product label); 2. Other comorbid conditions that may compromise assessing key outcomes or, in the judgement of the clinician, limit the ability of the patient to comply with the protocol.
Where this trial is running
Singapore
- National Cancer Centre, Singapore — Singapore, Singapore (Recruiting)
Study contacts
- Principal investigator: Daniel SW Tan, BSc(Hons), MBBS, MRCP, PhD — National Cancer Centre, Singapore
- Study coordinator: Daniel SW Tan, BSc(Hons), MBBS, MRCP, PhD
- Email: daniel.tan.s.w@singhealth.com.sg
- Phone: +65 64368000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.